Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 121

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 121
---
 | Cultivating long-term relationships and collaborations with key institutions, health organizations, like WHO and NIH, NGOs, and governments, especially in regions with high burdens of antibiotic-resistant infections. These partnerships can facilitate market access, drive adoption, and support public health initiatives. |

<div align='center'>77</div>

With respect to Development of ARB combination therapy, our strategy includes:

| ● | Early Collaborative Ventures: Initiate strategic collaborations with leading oncology-focused pharmaceutical companies early in the development cycle, particularly following promising preclinical results or early-phase clinical trial success. These collaborations could encompass licensing deals, co-development agreements, or joint ventures, aimed at leveraging external expertise and resources to accelerate ARB’s progression through clinical development and regulatory pathways. |

| ● | Target High-Impact                                                                                                                      
 Indications: Prioritize cancer indications where the tumor microenvironment (TME) significantly impacts treatment outcomes and          
 where current therapeutic options are limited. Focusing on these indications can potentially facilitate expedited regulatory approvals, 
 such as orphan drug status or breakthrough therapy designation, enhancing ARB’s attractiveness to potential partners and acquirers.     |

| ● | Strategic Regulatory Engagement: Pursue early and continuous engagement with regulatory bodies to navigate the development process efficiently, utilizing programs like the FDA’s Fast Track and Priority Review to shorten the timeline to market authorization. |

| ● | Robust IP Portfolio                                                                                                                    
 Development: Expand and protect the intellectual property landscape around main ARB patent, including its unique liposomal formulation 
 manufacturing methods and potential use cases across various solid tumors.                                                             |

| ● | Data Publication and Presentation: Strategically release clinical trial results and other key data milestones at major oncology conferences and in high-impact journals to maximize visibility and interest from the oncology community, investors, and potential acquirers. |

| ● | Timely Exit Considerations:                                                                                                        
 Evaluate exit opportunities following pivotal Phase 2 data, which often serves as an inflection point in valuation for emerging    
 oncology therapies, balancing the potential for further value appreciation against the risks and costs of later-stage development. |

| ● | Expanding Therapeutic Range: Broaden the scope of ARB’s development program to explore its potential across a diverse array of solid tumors, capitalizing on the versatility of the liposomal formulation to address multiple facets of the TME. This expansion can significantly enhance ARB’s market potential and long-term value. |

| ● | Enduring Partnerships and Collaborations: Forge and maintain strategic partnerships with academic institutions, research organizations